ATE289204T1 - Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie - Google Patents

Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie

Info

Publication number
ATE289204T1
ATE289204T1 AT00921056T AT00921056T ATE289204T1 AT E289204 T1 ATE289204 T1 AT E289204T1 AT 00921056 T AT00921056 T AT 00921056T AT 00921056 T AT00921056 T AT 00921056T AT E289204 T1 ATE289204 T1 AT E289204T1
Authority
AT
Austria
Prior art keywords
treating
preventing
inhibiting
progress
medicinal products
Prior art date
Application number
AT00921056T
Other languages
German (de)
English (en)
Inventor
Shizue Nakagawa
Yasutaka Nagisa
Hitoshi Ikeda
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE289204T1 publication Critical patent/ATE289204T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00921056T 1999-04-28 2000-04-27 Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie ATE289204T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12149899 1999-04-28
PCT/JP2000/002766 WO2000066161A1 (en) 1999-04-28 2000-04-27 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy

Publications (1)

Publication Number Publication Date
ATE289204T1 true ATE289204T1 (de) 2005-03-15

Family

ID=14812676

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921056T ATE289204T1 (de) 1999-04-28 2000-04-27 Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie

Country Status (23)

Country Link
US (2) US7064141B1 (cg-RX-API-DMAC7.html)
EP (1) EP1197223B1 (cg-RX-API-DMAC7.html)
KR (1) KR100865059B1 (cg-RX-API-DMAC7.html)
CN (1) CN1172719C (cg-RX-API-DMAC7.html)
AT (1) ATE289204T1 (cg-RX-API-DMAC7.html)
AU (1) AU774799B2 (cg-RX-API-DMAC7.html)
BR (1) BR0010084A (cg-RX-API-DMAC7.html)
CA (1) CA2371554C (cg-RX-API-DMAC7.html)
CZ (1) CZ301913B6 (cg-RX-API-DMAC7.html)
DE (1) DE60018186T2 (cg-RX-API-DMAC7.html)
DK (1) DK1197223T3 (cg-RX-API-DMAC7.html)
ES (1) ES2233362T3 (cg-RX-API-DMAC7.html)
HU (1) HU226948B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010923A (cg-RX-API-DMAC7.html)
NO (1) NO327446B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ514855A (cg-RX-API-DMAC7.html)
PL (1) PL196895B1 (cg-RX-API-DMAC7.html)
PT (1) PT1197223E (cg-RX-API-DMAC7.html)
RU (1) RU2239454C2 (cg-RX-API-DMAC7.html)
SI (1) SI1197223T1 (cg-RX-API-DMAC7.html)
SK (1) SK286859B6 (cg-RX-API-DMAC7.html)
WO (1) WO2000066161A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108527B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
TW200304812A (en) * 2002-03-08 2003-10-16 Sankyo Co An eye drop containing a tetrazole derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
TWI349549B (en) * 2003-04-15 2011-10-01 Sankyo Co Medicament for treatment of intraocular angiopoietic disease
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
WO2006024092A1 (en) * 2004-08-31 2006-03-09 Newsouth Innovations Pty Limited Vegf inhibition
DK1814527T4 (da) * 2004-11-05 2020-12-07 Boehringer Ingelheim Int Dobbeltlagstablet omfattende telmisartan og amlodipin
RU2420280C2 (ru) * 2005-04-21 2011-06-10 Сантен Фармасьютикал Ко., Лтд Терапевтическое средство против кератоконъюнктивального расстройства
KR20080074128A (ko) * 2005-12-06 2008-08-12 산텐 세이야꾸 가부시키가이샤 각결막 장애 치료제
PT2124903T (pt) * 2007-03-28 2019-09-26 Takeda Pharmaceuticals Co Composição farmacêutica sólida compreendendo um derivado de benzimidazole-7-carboxilato e um agente de controlo de ph

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
DE4201554A1 (de) * 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
GB9223860D0 (en) 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
MX9603259A (es) * 1994-02-08 1997-03-29 Novartis Ag Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
JPH09210183A (ja) * 1996-01-31 1997-08-12 Suzuki Motor Corp 動力伝達装置
NZ332008A (en) * 1996-03-29 1999-05-28 Smithkline Beecham Corp Eprosartan dihydrate and a process for its production and formulation
PL193365B1 (pl) * 1996-04-05 2007-02-28 Takeda Pharmaceutical Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz zastosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II
TW416953B (en) * 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2294515C (en) * 1997-06-27 2007-08-28 Smithkline Beecham Corporation Eprosartan monohydrate
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
CA2299470C (en) * 1997-08-06 2010-01-26 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
EP1058541B1 (en) 1998-03-04 2004-01-28 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
EP1096932B1 (en) 1998-07-10 2007-08-29 Novartis Pharma AG Antihypertensive combination of valsartan and calcium channel blocker
FR2783422A1 (fr) 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
JP2000159671A (ja) 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Also Published As

Publication number Publication date
NZ514855A (en) 2004-01-30
MXPA01010923A (es) 2002-06-21
EP1197223A1 (en) 2002-04-17
CA2371554A1 (en) 2000-11-09
BR0010084A (pt) 2002-01-15
CN1172719C (zh) 2004-10-27
CZ301913B6 (cs) 2010-07-28
AU774799B2 (en) 2004-07-08
EP1197223B1 (en) 2005-02-16
CA2371554C (en) 2009-06-09
KR20020015315A (ko) 2002-02-27
PL196895B1 (pl) 2008-02-29
EP1197223A4 (en) 2003-10-29
AU4143400A (en) 2000-11-17
HUP0200890A3 (en) 2002-12-28
US7064141B1 (en) 2006-06-20
DE60018186T2 (de) 2005-12-29
ZA200108527B (en) 2002-10-17
NO20015257D0 (no) 2001-10-26
HUP0200890A2 (hu) 2002-11-28
DE60018186D1 (de) 2005-03-24
HU226948B1 (en) 2010-03-29
SI1197223T1 (cg-RX-API-DMAC7.html) 2005-08-31
ES2233362T3 (es) 2005-06-16
PT1197223E (pt) 2005-04-29
DK1197223T3 (da) 2005-05-30
CZ20013804A3 (cs) 2002-04-17
US20060189669A1 (en) 2006-08-24
NO327446B1 (no) 2009-06-29
KR100865059B1 (ko) 2008-10-23
WO2000066161A1 (en) 2000-11-09
PL350554A1 (en) 2002-12-16
SK15452001A3 (sk) 2002-04-04
SK286859B6 (sk) 2009-06-05
CN1348385A (zh) 2002-05-08
RU2239454C2 (ru) 2004-11-10
NO20015257L (no) 2001-10-26

Similar Documents

Publication Publication Date Title
BR0109703A (pt) Derivados de piperazina
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
SE9903760D0 (sv) New compounds
GB0225475D0 (en) Therapeutic agents
ATE408601T1 (de) Fredericamycin-derivate
GB0318447D0 (en) Therapeutic agents
WO2003080582A3 (de) Fredericamycin-derivate
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
GB0222514D0 (en) Organic compounds
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ES2164109T3 (es) Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.
NO20000446D0 (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
DE69925270D1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1197223

Country of ref document: EP

REN Ceased due to non-payment of the annual fee